Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Bristol-Myers Squibb and Simcere to jointly develop BMS-817378

Nov. 8, 2010

Oncothyreon begins phase I/II trial of PX-866/docetaxel combination

Nov. 5, 2010

Adventrx Pharma submits NDA to FDA for vinorelbine

Nov. 5, 2010

Takeda and Millennium initiate phase III TAK-700 program in prostate cancer

Nov. 5, 2010

New progesterone receptor antagonists presented by Evestra

Nov. 5, 2010

Interim phase I/II data presented on dovitinib in RCC

Nov. 5, 2010

Preliminary phase II/III data disclosed on fosbretabulin plus chemotherapy in ATC

Nov. 5, 2010

MLN-8237 shows promise in epithelial ovarian, fallopian tube and primary peritoneal carcinoma

Nov. 5, 2010

Gynecologic Oncology Group to begin phase II elesclomol trial in ovarian cancer

Nov. 4, 2010

Viralytics submits IND for phase II trial of Cavatak in melanoma

Nov. 4, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...